ELECTRA breast cancer trial

Study overview

California Research Institute lists ELECTRA as an open-label, multicenter Phase 1b/2 breast cancer study. The research evaluates elacestrant in combination with abemaciclib in women and men who have brain metastases from estrogen receptor-positive, HER2-negative breast cancer. The supplied study listing identifies the Phase 2 breast-cancer-with-brain-metastases cohort as open to enrollment; current availability must be confirmed directly with the research team.

What the research examines

Elacestrant is being studied together with abemaciclib in this specific clinical setting. An open-label design means participants and investigators know which study treatment is administered. A multicenter design means the same research protocol may be conducted at more than one participating location. Phase 1b research commonly examines safety, tolerability, and dose-related questions, while Phase 2 research further evaluates study activity and safety in the defined population. Individual eligibility cannot be determined from this website.

Asking about participation

A research coordinator can explain whether the local cohort is currently accepting inquiries, describe the screening process, and review the official eligibility criteria with you. Contacting the institute does not enroll you, guarantee eligibility, or replace advice from your oncology team. Participation is voluntary, and potential risks, procedures, alternatives, and possible benefits are discussed through the informed-consent process before enrollment.

The study team may also explain visit expectations, required evaluations, and whom to contact with questions, using the current protocol and consent materials as the authoritative sources.

To ask about current availability, use the secure information-request form. Do not include medical records, insurance details, or other sensitive health information. A coordinator will review the inquiry and respond.

View all clinical trials